Last updated: September 9, 2026
Lamivudine/zidovudine is the fixed-dose antiretroviral combination marketed primarily as Combivir. Its commercial value has declined sharply because the product contains two older nucleoside reverse transcriptase inhibitors, both available as low-cost generics and largely replaced in first-line HIV treatment by tenofovir-based and integrase-inhibitor regimens. The combination remains relevant in selected treatment settings, but it is no longer a major growth product or material innovation asset.
What is lamivudine/zidovudine and who markets it?
Lamivudine/zidovudine combines:
| Component |
Drug class |
Original branded product |
| Lamivudine |
Nucleoside reverse transcriptase inhibitor |
Epivir |
| Zidovudine |
Nucleoside reverse transcriptase inhibitor |
Retrovir |
| Fixed-dose combination |
Two-NRTI antiretroviral |
Combivir |
The U.S. Food and Drug Administration approved Combivir in September 1997. Glaxo Wellcome, later part of GlaxoSmithKline, developed and commercialized the product. HIV assets are now managed through ViiV Healthcare, the specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders.
Combivir is administered orally, generally as one tablet containing 150 mg of lamivudine and 300 mg of zidovudine twice daily. The product was designed to reduce pill burden compared with taking Epivir and Retrovir separately.
The product’s commercial position weakened as treatment guidelines shifted toward:
- Tenofovir disoproxil fumarate or tenofovir alafenamide combinations.
- Integrase strand transfer inhibitor regimens.
- Once-daily fixed-dose combinations.
- Regimens with improved tolerability, lower mitochondrial toxicity, and fewer hematologic adverse effects.
The U.S. prescribing information states that Combivir is not recommended as initial therapy because the fixed doses prevent adjustment and because zidovudine has important toxicity limitations, including anemia and neutropenia [1].
When does lamivudine/zidovudine lose exclusivity?
U.S. exclusivity for the combination has expired. The core commercial patents protecting the individual components and the fixed-dose product are no longer effective barriers to generic competition.
Key U.S. patent and exclusivity milestones
| Asset |
Principal company |
Approximate U.S. milestone |
Commercial impact |
| Zidovudine |
Burroughs Wellcome/Glaxo Wellcome |
Core exclusivity expired before the Combivir launch era |
Generic zidovudine became available |
| Lamivudine |
Glaxo Wellcome |
Core exclusivity expired in the late 2000s |
Generic lamivudine entered |
| Combivir fixed-dose product |
Glaxo Wellcome/GSK |
Core patent protection expired in the mid-2010s |
Fixed-dose generic competition became possible |
| Pediatric exclusivity |
Brand sponsor |
Added six months to certain eligible protections |
No longer commercially relevant |
The exact patent portfolio varied by jurisdiction and by claim type. Relevant protection included composition-of-matter patents for the active ingredients, combination-product claims, pharmaceutical-composition claims, and manufacturing or process patents. The principal U.S. combination patent commonly associated with Combivir was U.S. Patent No. 5,580,859, which reached the end of its effective commercial life in the mid-2010s after applicable adjustments and extensions.
Patent expiry did not create a single global launch date. Generic entry depended on local patent law, regulatory filing rules, product registration, procurement contracts, and the availability of approved single-agent products.
What is the FDA regulatory status of lamivudine/zidovudine?
Combivir remains an FDA-approved prescription product, but its role is narrow compared with newer antiretroviral therapies. FDA approval does not imply current guideline preference or commercial growth.
The main regulatory characteristics are:
| Regulatory issue |
Status |
| Product type |
Small-molecule fixed-dose combination |
| FDA pathway |
New drug application originally submitted by the innovator |
| Generic pathway |
Abbreviated New Drug Application |
| Biosimilar pathway |
Not applicable |
| Orange Book relevance |
Applicable to listed brand patents and exclusivity |
| Current clinical role |
Limited and generally not preferred for initial therapy |
| Primary alternatives |
Tenofovir-based combinations and integrase-inhibitor regimens |
The product is not a biologic and therefore has no biosimilar exposure. Its competitive risk comes from conventional generic drugs and therapeutic substitution, not biosimilar interchangeability.
FDA labeling identifies warnings associated with both active ingredients. Zidovudine is associated with bone-marrow suppression, myopathy, lactic acidosis, and hepatic steatosis. Lamivudine requires attention to hepatitis B coinfection because discontinuation can cause hepatitis B exacerbation [1].
What patents protect lamivudine/zidovudine?
The historical patent estate had four principal layers.
Active-ingredient patents
Lamivudine and zidovudine were each protected originally by compound patents and related pharmaceutical claims. Those patents created the first commercial exclusivity for Epivir and Retrovir but are now expired in the major markets.
Fixed-dose combination patents
Combination patents covered the use of lamivudine and zidovudine in a single dosage form. These claims supported Combivir’s commercial position after the individual agents were already known.
Formulation patents
Formulation claims addressed tablet composition, excipients, stability, dissolution, and manufacturing parameters. These patents could delay direct substitution by an identical tablet but generally did not prevent competition from separate lamivudine and zidovudine tablets.
Method-of-use patents
Method-of-use claims covered treatment of HIV infection with the active ingredients. Their practical value declined as broad treatment claims expired and as clinical practice moved toward other regimens. Method-of-use patents may still have had relevance in certain jurisdictions, but they do not provide a meaningful global barrier to generic use today.
The estate is therefore weak from a present-day blocking perspective. It has historical value for reconstructing the originator’s exclusivity strategy but limited value as a current licensing or litigation asset.
How many patents cover lamivudine/zidovudine today?
No single global patent count accurately represents current protection because patent families differ by country, continuation practice, terminal disclaimers, pediatric extensions, and claim scope. In the United States, the commercially material patents for the original combination have expired.
The relevant distinction is between:
- Expired patents covering the active ingredients.
- Expired patents covering the fixed-dose combination.
- Potentially surviving process or formulation claims with narrow scope.
- Country-specific rights that may have expired at different times.
Narrow manufacturing patents may still appear in patent databases, but they generally do not prevent generic companies from producing lamivudine, zidovudine, or a bioequivalent combination through alternative processes.
Were there Paragraph IV challenges to Combivir?
Paragraph IV filings were relevant to generic entry because an ANDA applicant could certify that listed patents were invalid, unenforceable, or not infringed. The most commercially important challenges targeted the patents that protected the fixed-dose combination and the underlying active ingredients.
The litigation profile was more significant before the major patents expired. After expiration, the commercial incentive to sustain extensive litigation diminished because:
- The active ingredients were already generic.
- Physicians had shifted toward newer regimens.
- Separate generic tablets were available.
- The expected price of a fixed-dose generic was low.
- The brand had limited ability to preserve premium pricing.
Publicly disclosed Combivir litigation has historically involved Glaxo Wellcome or GSK and generic applicants seeking approval. The disputes were primarily Hatch-Waxman matters concerning patent validity, infringement, and the timing of ANDA approval. There is no current patent dispute that creates a material U.S. barrier to generic lamivudine/zidovudine entry.
What is the Orange Book status of Combivir?
Combivir’s Orange Book relevance is historical rather than strategic. The Orange Book identifies approved drug products, therapeutic equivalence information, patents submitted by sponsors, and applicable exclusivity information.
For commercial analysis, the key points are:
- The product is an approved small-molecule drug.
- Listed patents protecting the original commercial product have reached expiration.
- Generic substitution depends on the approval and therapeutic-equivalence status of individual products.
- Orange Book listing does not prevent treatment substitution with separate generic lamivudine and zidovudine.
- The combination’s listing does not restore exclusivity for the underlying molecules.
A generic company can compete in two ways: by marketing the same fixed-dose combination or by selling the two active ingredients separately. The second route is clinically and economically important because physicians and procurement systems may accept separate tablets even when a fixed-dose version is unavailable.
How has the market for lamivudine/zidovudine changed?
The market has moved through four stages.
1. Early combination-antiretroviral expansion
In the late 1990s and early 2000s, Combivir was a high-value product because it simplified a multidrug HIV regimen. Fixed-dose combinations improved adherence and reduced prescribing complexity.
2. Generic erosion of the individual ingredients
Generic zidovudine and lamivudine reduced the value of buying the branded components. This weakened the pricing power of Combivir and made separate-tablet regimens economically competitive.
3. Replacement by newer combinations
Tenofovir/emtricitabine products and later integrase-inhibitor combinations became preferred because they offered better tolerability, simpler dosing, and stronger guideline support. Products such as Atripla, Stribild, Genvoya, Triumeq, Biktarvy, and other modern regimens changed the treatment standard.
4. Residual and access-driven demand
Demand persists in certain low-income and middle-income markets, public-health programs, legacy patients, and situations where clinicians require an alternative based on renal function, pregnancy considerations, prior treatment history, or local formulary availability. That demand is generally price-sensitive and procurement-driven.
The result is a mature, declining market with limited product differentiation.
What is the financial trajectory of lamivudine/zidovudine?
Combivir’s financial trajectory is best described as a transition from branded growth product to low-margin legacy product.
| Period |
Financial profile |
| 1997-2002 |
Strong adoption as a convenient dual-NRTI backbone |
| 2003-2008 |
Mature branded sales, rising pressure from separate generics and competing combinations |
| 2009-2015 |
Declining revenue as component patents expired and newer regimens expanded |
| After 2015 |
Generic erosion, lower average selling price, and limited strategic importance |
| Current market |
Residual revenue concentrated in selected geographies and institutional channels |
GSK and ViiV do not generally report Combivir revenue as a separate major line item in current financial disclosures. The product is included within broader HIV or established-product reporting, making a precise current global revenue figure unavailable from public company segment reporting. Its contribution is immaterial compared with newer ViiV products such as dolutegravir- and cabotegravir-based therapies.
The economic drivers are unfavorable:
- Low generic pricing.
- Limited prescription growth.
- Therapeutic substitution.
- Declining branded market share.
- Public-sector tender pressure.
- No meaningful patent-based price protection.
- Low probability of a large new indication.
The product may still generate positive contribution margin in markets where ViiV retains brand recognition or distribution access, but it is unlikely to justify major development investment.
What generic launch scenarios exist for lamivudine/zidovudine?
Three generic scenarios are commercially plausible.
Same-product fixed-dose generic entry
A company markets a bioequivalent tablet containing 150 mg lamivudine and 300 mg zidovudine. This is the most direct substitute for Combivir.
Separate-component substitution
Healthcare systems use generic lamivudine and zidovudine tablets separately. This option often provides the lowest acquisition cost and can compete even if a fixed-dose generic has limited distribution.
Regional tender-based supply
Manufacturers compete for government and donor-funded procurement contracts. Price, World Health Organization prequalification, manufacturing capacity, quality documentation, and supply reliability may matter more than brand recognition.
U.S. generic entry risk is high because core patent barriers have expired. In emerging markets, the principal barriers are regulatory registration, procurement qualification, working capital, and supply-chain execution rather than patent infringement.
Which companies compete with lamivudine/zidovudine?
Competition comes from both generic suppliers and newer branded therapies.
Direct generic competitors
Potential competitors include manufacturers of generic lamivudine, generic zidovudine, and fixed-dose combinations. Suppliers vary by market and may include large multinational generic companies, regional manufacturers, and public-health-oriented producers.
Therapeutic competitors
The most important competitors are newer antiretroviral regimens:
| Competitive category |
Examples |
Competitive advantage |
| Tenofovir-based dual-NRTI backbones |
Tenofovir/emtricitabine; tenofovir/lamivudine |
Better guideline positioning and dosing convenience |
| Integrase-inhibitor combinations |
Dolutegravir- or bictegravir-based regimens |
High potency and high resistance barrier |
| Long-acting therapy |
Cabotegravir/rilpivirine |
Reduced daily pill burden |
| Alternative NRTI combinations |
Abacavir/lamivudine |
Relevant in selected patients |
These products compete for treatment initiation, not only for patients already using Combivir. That makes therapeutic displacement more important than direct generic substitution.
How strong is the patent estate for lamivudine/zidovudine?
The current patent estate is weak. Its historical strength was high enough to support branded commercialization, but its present value is limited by expiration and therapeutic obsolescence.
| Patent-strength factor |
Assessment |
| Core compound protection |
Expired |
| Fixed-dose combination protection |
Expired in major markets |
| Formulation protection |
Mostly expired or narrow |
| Method-of-use protection |
Limited practical value |
| Manufacturing protection |
Potentially narrow and design-aroundable |
| Biosimilar barrier |
Not applicable |
| Generic blocking power |
Low |
| Licensing value |
Low, except for regional supply or technology arrangements |
The absence of a meaningful current patent barrier does not eliminate manufacturing risk. A supplier still must demonstrate consistent tablet quality, dissolution, stability, impurity control, and bioequivalence. Zidovudine manufacturing also requires control of active pharmaceutical ingredient quality and occupational handling processes. These are execution barriers, not durable exclusivity barriers.
What licensing deals affect lamivudine/zidovudine?
The most important historical commercial arrangement was the development and commercialization of lamivudine and zidovudine within the Glaxo Wellcome HIV portfolio and the later formation of ViiV Healthcare.
Current licensing value is limited. Potential arrangements are more likely to involve:
- Voluntary licensing for access programs.
- Regional distribution.
- Public-sector procurement.
- Technology transfer for generic supply.
- Portfolio licensing covering multiple antiretroviral products.
A standalone Combivir license is unlikely to command significant economics because the product is mature, off-patent, and exposed to therapeutic substitution.
What patent litigation and settlement issues remain?
No present litigation involving Combivir appears likely to change the product’s commercial trajectory in the United States. Historical disputes centered on generic entry and patent validity. Any settlement would have had its principal economic effect before expiration of the relevant patents.
For investors and licensing teams, the practical conclusion is direct: litigation risk is low, but the absence of litigation reflects the age and low strategic value of the asset rather than a strong patent position.
What geographic markets remain commercially relevant?
The product’s residual demand is most likely in:
- Low- and middle-income countries.
- Public-health treatment programs.
- Markets with slower adoption of integrase-inhibitor regimens.
- Formularies with established procurement of lamivudine and zidovudine.
- Regions where generic fixed-dose combinations reduce pill burden at low cost.
High-income markets have the greatest substitution pressure because newer regimens are widely available and treatment guidelines have moved away from zidovudine-based initial therapy.
Geographic patent coverage is no longer the main determinant of sales. Regulatory approval, WHO or local quality qualification, tender access, and manufacturing economics are more important.
Key Takeaways
- Lamivudine/zidovudine is the fixed-dose antiretroviral combination historically marketed as Combivir.
- FDA approval dates to 1997, but the product is no longer a preferred initial HIV regimen.
- Core compound and combination patents have expired in major markets.
- Paragraph IV and Hatch-Waxman disputes were historically relevant but do not create a current U.S. entry barrier.
- Biosimilar risk is irrelevant because the product is a small-molecule drug.
- Generic competition affects both the fixed-dose product and the separate active ingredients.
- Tenofovir- and integrase-inhibitor-based regimens are the main sources of therapeutic displacement.
- Current branded revenue is not separately disclosed and is likely immaterial relative to ViiV’s newer HIV products.
- The remaining commercial opportunity is concentrated in price-sensitive, institutional, and emerging-market channels.
- The patent estate has low current strength and limited licensing value.
FAQs about lamivudine/zidovudine patents, revenue, and competition
Is Combivir still under patent protection?
No. The principal U.S. patents protecting lamivudine, zidovudine, and the fixed-dose combination have expired. Narrow country-specific or process claims may differ, but they do not create a broad global barrier.
Can generic companies sell lamivudine/zidovudine in the United States?
Yes, subject to FDA approval and applicable product-specific requirements. Generic companies can also compete by selling lamivudine and zidovudine as separate tablets.
Is lamivudine/zidovudine recommended for first-line HIV treatment?
Generally no. Current treatment practice favors integrase-inhibitor-based regimens with newer NRTI backbones because of dosing, tolerability, and resistance considerations.
Does ViiV disclose Combivir sales separately?
ViiV and GSK generally report HIV revenue at a broader portfolio level rather than providing a current standalone Combivir revenue line. The product is not a major disclosed growth driver.
What is the main investment risk for lamivudine/zidovudine?
The main risk is structural revenue erosion from generic pricing and therapeutic substitution. Patent expiry is already reflected in the product’s mature commercial status, so additional litigation is unlikely to restore meaningful exclusivity.
References
- U.S. Food and Drug Administration. (2023). Combivir: Prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov
- National Institutes of Health. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. https://clinicalinfo.hiv.gov
- ViiV Healthcare. (2024). Annual and corporate reports. https://viivhealthcare.com
- World Health Organization. (2024). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. https://www.who.int
- U.S. Patent and Trademark Office. (2024). Patent Center and patent term information. https://patentcenter.uspto.gov
